Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Kivu Bioscience Inc.
Exscientia AI Limited
AstraZeneca
Sotio Biotech Inc.
Radiopharm Theranostics, Ltd
PMV Pharmaceuticals, Inc
Neonc Technologies, Inc.
Radiopharm Theranostics, Ltd
Tasca Therapeutics
MacroGenics
MacroGenics
SystImmune Inc.
SN BioScience
Boundless Bio, Inc.
ImmunityBio, Inc.
VM Oncology, LLC
DualityBio Inc.
Incyte Corporation
Janux Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
University of Colorado, Denver
Merck Sharp & Dohme LLC
Incyte Corporation
A2 Biotherapeutics Inc.
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
Marengo Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
OncoC4, Inc.
Klus Pharma Inc.
Hutchmed
Theratechnologies
SOLTI Breast Cancer Research Group
Cofactor Genomics, Inc.
Seagen Inc.
AstraZeneca
Cyteir Therapeutics, Inc.
BeiGene
Carisma Therapeutics Inc
Travera Inc
Salubris Biotherapeutics Inc
Merck Sharp & Dohme LLC
Pfizer
Xencor, Inc.
TransThera Sciences (Nanjing), Inc.
Evopoint Biosciences Inc.
MacroGenics
Fate Therapeutics
Shanghai Yunying Medical Technology